Otello Stampacchia

Otello Stampacchia

Chief Executive Officer bei OMEGA ALPHA SPAC

Vermögen: 54 567 $ am 31.03.2024

55 Jahre
Health Technology
Finance
Commercial Services

Profil

Otello Stampacchia is the founder of Omega Fund Management LLC, which was founded in 2004, and Omega Alpha SPAC, which was founded in 2020.
He is currently the Chairman of Aerium Therapeutics, Inc. and a Director at Scorpion Therapeutics, Inc., Photys Therapeutics, Inc., Amunix Pharmaceuticals, Inc., Ikena Oncology, Inc., Morphic Therapeutic, Inc., and Rectify Pharmaceuticals LLC.
Dr. Stampacchia has held former positions as a Director at SpineVision SA, CropDesign NV, Paratek Pharmaceuticals, Inc., ESSA Pharma, Inc., Translate Bio, Inc., Kronos Bio, Inc., Nuvation Bio Operating Co., Inc., Trident Pharmaceuticals, Inc., Exonhit, MEDIAN Technologies SA, Trevi Therapeutics, Inc., FibroGen, Inc., DeveloGen AG, Intarcia Therapeutics, Inc., Gossamer Bio, Inc., Andrew Alliance SA, Morphic Holding, Inc., BioVex, Inc., Replimune Group, Inc., Juno Therapeutics, Inc., Achaogen, Inc., Micromet AG, AlpInvest Partners BV, and LODH Immunology Fund.
He was also an Associate at The Goldman Sachs Group, Inc. from 1996 to 2000.
Dr. Stampacchia received a graduate degree from the University of Pavia in 1996 and a doctorate degree from the University of Geneva in 1996.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
08.09.2023 19 568 ( 0,04% ) 27 787 $ 31.03.2024
31.12.2022 20 600 ( 0,03% ) 26 780 $ 31.03.2024

Aktive Positionen von Otello Stampacchia

UnternehmenPositionBeginn
IKENA ONCOLOGY, INC. Director/Board Member 01.12.2020
OMEGA ALPHA SPAC Chief Executive Officer 26.10.2020
Director/Board Member 01.10.2020
Director/Board Member -
Chairman -
Director/Board Member -
Founder 01.01.2004
Director/Board Member 24.09.2018
Director/Board Member -
Alle aktiven Positionen von Otello Stampacchia

Ehemalige bekannte Positionen von Otello Stampacchia

UnternehmenPositionEnde
░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Otello Stampacchia im Detail an

Ausbildung von Otello Stampacchia

University of Pavia Graduate Degree
University of Geneva Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Otello Stampacchia im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

37

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen10
THE GOLDMAN SACHS GROUP, INC.

Finance

FIBROGEN, INC.

Health Technology

MEDIAN TECHNOLOGIES

Health Services

ESSA PHARMA INC.

Health Technology

TREVI THERAPEUTICS, INC.

Health Technology

REPLIMUNE GROUP, INC.

Health Technology

MORPHIC HOLDING, INC.

Health Technology

IKENA ONCOLOGY, INC.

Health Technology

GOSSAMER BIO, INC.

Health Technology

KRONOS BIO, INC.

Health Technology

Private Unternehmen25

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Health Technology

LODH Immunology Fund

Finance

Finance

Health Technology

Health Technology

Producer Manufacturing

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

Commercial Services

Health Technology

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Otello Stampacchia